Levels of Matrix Metalloproteinases Differ in Plasma and Serum - Aspects Regarding Analysis of Biological Markers in Cancer

Overview

Journal Br J Cancer

Specialty Oncology

Date 2016 May 18

PMID 27187685

Citations 24

Authors

Andreas Jonsson

Claes Hjalmarsson

Peter Falk

Marie-Lois Ivarsson

Affiliations

Soon will be listed here.

Abstract

Background: There are inconsistencies in the use of serum or plasma when analysing the matrix metalloproteinases (MMPs) as diagnostic or prognostic markers. The purpose of this study was to compare the concentration of MMP-1, -2, -7, -8, -9 and -13 in serum vs plasma samples.

Methods: Blood samples were obtained from sixty-five men and women. Samples were analysed for levels of MMPs in corresponding citrate plasma and serum.

Results: All MMPs expressed higher concentration in serum compared with plasma (P<0.01). There were no differences between genders.

Conclusions: Present study demonstrated significant differences regarding concentrations of some MMPs using plasma vs serum. We conclude that future studies regarding MMPs as biological markers in cancer should consider the use of citrate plasma instead of serum.

Citing Articles

Injectable Shear-Thinning Hydrogels with Sclerosing and Matrix Metalloproteinase Modulatory Properties for the Treatment of Vascular Malformations.

Zehtabi F, Gangrade A, Tseng K, Haghniaz R, Abasgholizadeh R, Montazerian H Adv Funct Mater. 2024; 33(51).

PMID: 38558868 PMC: 10977963. DOI: 10.1002/adfm.202305880.

Matrix metalloproteinase responsive hydrogel microplates for programmed killing of invasive tumour cells.

Cook A, Palange A, Schlich M, Bellotti E, Brahmachari S, di Francesco M RSC Appl Polym. 2023; 1(1):19-29.

PMID: 38013908 PMC: 10540463. DOI: 10.1039/d3lp00057e.

Potential biomarkers to predict return to fertility after discontinuation of female contraceptives-looking to the future.

Cordova-Gomez A, Wong A, Sims L, Doncel G, Dorflinger L Front Reprod Health. 2023; 5:1210083.

PMID: 37674657 PMC: 10477712. DOI: 10.3389/frph.2023.1210083.

Substrate derived sequences act as subsite-blocking motifs in protease inhibitory antibodies.

Choe H, Antee T, Ge X Protein Sci. 2023; 32(7):e4691.

PMID: 37278099 PMC: 10285753. DOI: 10.1002/pro.4691.

Development of In Vitro Dry Eye Models to Study Proliferative and Anti-Inflammatory Effects of Allogeneic Serum Eye Drops.

Voss S, Behrmann T, Reichl S Int J Mol Sci. 2023; 24(2).

PMID: 36675083 PMC: 9864688. DOI: 10.3390/ijms24021567.

References

Maurel J, Nadal C, Garcia-Albeniz X, Gallego R, Carcereny E, Almendro V . Serum matrix metalloproteinase 7 levels identifies poor prognosis advanced colorectal cancer patients. Int J Cancer. 2007; 121(5):1066-71. DOI: 10.1002/ijc.22799. View

Damery S, Nichols L, Holder R, Ward S, Warmington S, Wilson S . Assessing the value of matrix metalloproteinase 9 (MMP9) in improving the appropriateness of referrals for colorectal cancer. Br J Cancer. 2013; 108(5):1149-56. PMC: 3619067. DOI: 10.1038/bjc.2013.49. View

Fontana V, Silva P, Gerlach R, Tanus-Santos J . Circulating matrix metalloproteinases and their inhibitors in hypertension. Clin Chim Acta. 2012; 413(7-8):656-62. DOI: 10.1016/j.cca.2011.12.021. View

Gerlach R, Demacq C, Jung K, Tanus-Santos J . Rapid separation of serum does not avoid artificially higher matrix metalloproteinase (MMP)-9 levels in serum versus plasma. Clin Biochem. 2006; 40(1-2):119-23. DOI: 10.1016/j.clinbiochem.2006.10.007. View

Zucker S, Cao J . Measurement of matrix metalloproteinases in serum of patients with melanoma: snarled in technical pitfalls. Clin Cancer Res. 2005; 11(14):5069-70. DOI: 10.1158/1078-0432.CCR-05-0774. View

Wu C, Wu M, Chiang E, Chen Y, Chen C, Chi N . Plasma matrix metalloproteinase-9 level is better than serum matrix metalloproteinase-9 level to predict gastric cancer evolution. Clin Cancer Res. 2007; 13(7):2054-60. DOI: 10.1158/1078-0432.CCR-06-2299. View

Zucker S, Hymowitz M, Conner C, Zarrabi H, Hurewitz A, Matrisian L . Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications. Ann N Y Acad Sci. 1999; 878:212-27. DOI: 10.1111/j.1749-6632.1999.tb07687.x. View

Kushlinskii N, Gershtein E, Korotkova E, Prorokov V . Prognostic role of tumor-associated proteases in colorectal cancer. Bull Exp Biol Med. 2013; 154(3):365-9. DOI: 10.1007/s10517-013-1952-4. View

Hurst N, Stocken D, Wilson S, Keh C, Wakelam M, Ismail T . Elevated serum matrix metalloproteinase 9 (MMP-9) concentration predicts the presence of colorectal neoplasia in symptomatic patients. Br J Cancer. 2007; 97(7):971-7. PMC: 2360395. DOI: 10.1038/sj.bjc.6603958. View

10.

Alby C, Ben Abdesselam O, Foglietti M, Beaudeux J . Preanalytical aspects regarding the measurement of metalloproteinase-9 and tissue inhibitor or metalloproteinase-1 in blood. Clin Chim Acta. 2002; 325(1-2):183-6. DOI: 10.1016/s0009-8981(02)00247-4. View

11.

Kusnierova P, Vsiansky F, Pleva L, Plevova P, Safarcik K, Svagera Z . Reference intervals of plasma matrix metalloproteinases 2, 3, and 9 and serum asymmetric dimethylarginine levels. Scand J Clin Lab Invest. 2015; 75(6):508-13. DOI: 10.3109/00365513.2015.1057760. View

12.

Cauwe B, Van den Steen P, Opdenakker G . The biochemical, biological, and pathological kaleidoscope of cell surface substrates processed by matrix metalloproteinases. Crit Rev Biochem Mol Biol. 2007; 42(3):113-85. DOI: 10.1080/10409230701340019. View

13.

Jung K, Meisser A, Bischof P . Blood sampling as critical preanalytical determinant to use circulating MMP and TIMP as surrogate markers for pathological processes. Int J Cancer. 2005; 116(6):1000-1. DOI: 10.1002/ijc.21129. View

14.

Gerlach R, Meschiari C, Marcaccini A, Palei A, Sandrim V, Cavalli R . Positive correlations between serum and plasma matrix metalloproteinase (MMP)-2 or MMP-9 levels in disease conditions. Clin Chem Lab Med. 2009; 47(7):888-91. DOI: 10.1515/CCLM.2009.203. View

15.

Jung K, Klotzek S, Stephan C, Mannello F, Lein M . Impact of blood sampling on the circulating matrix metalloproteinases 1, 2, 3, 7, 8, and 9. Clin Chem. 2008; 54(4):772-3. DOI: 10.1373/clinchem.2007.099937. View

16.

Langenskiold M, Holmdahl L, Falk P, Ivarsson M . Increased plasma MMP-2 protein expression in lymph node-positive patients with colorectal cancer. Int J Colorectal Dis. 2004; 20(3):245-52. DOI: 10.1007/s00384-004-0667-4. View

17.

Jung K . Is serum matrix metalloproteinase 9 a useful biomarker in detection of colorectal cancer? Considering pre-analytical interference that may influence diagnostic accuracy. Br J Cancer. 2008; 99(3):553-4. PMC: 2527787. DOI: 10.1038/sj.bjc.6604491. View

18.

Tutton M, George M, Eccles S, Burton S, Swift R, Abulafi A . Use of plasma MMP-2 and MMP-9 levels as a surrogate for tumour expression in colorectal cancer patients. Int J Cancer. 2003; 107(4):541-50. DOI: 10.1002/ijc.11436. View

19.

Mannello F, Tonti G . Gelatinase concentrations and zymographic profiles in human breast cancer: matrix metalloproteinases circulating in plasma are better markers for the subclassification and early prediction of cancer: the coagulation/fibrinolysis pathways alter the.... Int J Cancer. 2007; 121(1):216-8. DOI: 10.1002/ijc.22652. View

20.

Gerlach R, Uzuelli J, Souza-Tarla C, Tanus-Santos J . Effect of anticoagulants on the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities. Anal Biochem. 2005; 344(1):147-9. DOI: 10.1016/j.ab.2005.04.038. View